HAOHAI BIOTEC (06826) plans to acquire approximately 19.8% of the equity of Jiangxi Ruiji Biological Engineering Technology Co., Ltd.

HAOHAI BIOTEC (06826) announced that on December 12, 2025, the company and Zhong Xiaoyan plan to respectively acquire approximately 19.8% and 2.4554% of the equity of Jiangxi Ruiji Biological Engineering Technology Co., Ltd., at a cost of approximately 38.3515 million yuan and 4.756 million yuan respectively. The products of the target company are mainly used in the fields of orthopedics and ophthalmology, for tendon injury repair, corneal burns, wound and injury repair, and tear duct stenting after unblocking. By investing in the target company and obtaining the distribution rights of the target company's products in China, the group will be able to enter the high value-added medical device market of biological amniotic membrane, supplement the existing product portfolio, and expand its business layout in the orthopedics and ophthalmology fields. At the same time, the amniotic membrane material held by the target company has human biological characteristics, providing the group with key technology and material foundation in the field of regenerative medicine and tissue engineering, which is expected to drive subsequent product innovation and technological upgrades.